share_log

Roth MKM Maintains Buy on Champions Oncology, Lowers Price Target to $7.5

Benzinga ·  Sep 22, 2023 11:40

Roth MKM analyst Scott Henry maintains Champions Oncology (NASDAQ:CSBR) with a Buy and lowers the price target from $9 to $7.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment